Puma Biotechnology (PBYI) EPS (Basic) (2010 - 2026)

Puma Biotechnology (PBYI) has 16 years of EPS (Basic) data on file, last reported at -$0.07 in Q1 2026.

• Quarterly EPS (Basic) fell 223.09% year-over-year to -$0.07 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $0.55 (up 256.25% YoY) and the FY2025 annual result came in at $0.69, up 19296.54% from the prior year.
• EPS (Basic) eased to -$0.07 in Q1 2026, from $0.34 in the prior quarter.
• In the past five years, EPS (Basic) ranged from a high of $0.41 in Q3 2024 to a low of -$0.23 in Q4 2024.
• A 5-year average of $0.06 and a median of $0.05 in 2023 frame the typical range for EPS (Basic).
• Annual changes were most pronounced in 2023 — EPS (Basic) soared 1643.85% — and 2024, when it sank 432.61%.
• Tracing PBYI's EPS (Basic) over 5 years: stood at -$0.12 in 2022, then surged by 329.01% to $0.26 in 2023, then plunged by 186.78% to -$0.23 in 2024, then soared by 247.13% to $0.34 in 2025, then sank by 121.89% to -$0.07 in 2026.
• The last three EPS (Basic) figures came in at -$0.07 (Q1 2026), $0.34 (Q4 2025), and $0.18 (Q3 2025), per Business Quant data.